Alumis
IPOTransform Therapies, Reimagine Lives
Public · South San Francisco, United States · Founded 2021 · $459.0M raised
- Headquarters
- South San Francisco, California
- Employees
- 201–500
- Founded
- 2021
- Business Model
- B2B
- Website
- alumis.com
- Total Funding
- $459.0M
- Last Round
- $259.0M Series CMar 2024
- Rounds
- 2
- Type
- Public
About
Alumis is a clinical-stage biopharmaceutical company advancing a late-stage portfolio of next-generation oral targeted therapies for patients with immune-mediated diseases including psoriasis, lupus, and thyroid eye disease. The company's precision approach leverages proprietary data analytics to optimize clinical outcomes across a broad range of conditions.
Summary
Alumis is a Healthcare company based in South San Francisco, United States, founded in 2021. It has raised $459.0M in total across 2 rounds, most recently a $259.0M Series C round in Mar 2024. Investors include Foresite Capital, Samsara BioCapital and venBIO Partners.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jun 2024
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Alphabet-backed biotechnology company researching biology of aging and developing interventions t...
PHC is a leading provider of diabetes monitoring systems, specialized laboratory equipment, and c...
BridgeBio makes targeted treatments for genetic diseases.
Provides comprehensive molecular profiling and AI-driven precision oncology services for physicia...